Home / Medical Devices / Companion Diagnostics Market By Indication (Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Diseases), By Technology (Polymerase Chain Reaction, Immunohistochemistry (IHC), In-Situ Hybridization Test (ISH), Gene Sequencing, Others) - Growth, Share, Opportunities, Competitive Analysis, and Forecast 2016 – 2023

Companion Diagnostics Market By Indication (Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Diseases), By Technology (Polymerase Chain Reaction, Immunohistochemistry (IHC), In-Situ Hybridization Test (ISH), Gene Sequencing, Others) - Growth, Share, Opportunities, Competitive Analysis, and Forecast 2016 – 2023

Published: Sep 2016 | Report Code: 58078-09-16

Companion diagnostic tests are used to identify suitable patients for administering specific drugs and monitoring the prognosis of drug effects on the disease. This concept of combining a drug with a diagnostic test is known as predictive medicine or personalized medicine. A companion diagnostic test has the ability to predict the risks of the disease and monitor its therapeutic response. The tests enable physicians to make decisions on the type of drugs and dosage administration and thereby reduce the mortality rates associated with diseases such as cancer and neurodegenerative disorders. The global companion diagnostics market is expected to witness significant growth during the forecast period primarily by the growing focus on cost cutting in drug discovery and development. Asia Pacific is expected to grow at a highest rate during the forecast period due increased adoption, technological advancements, and demand for personalized medicine. Vendors in the market are focusing on several strategies such as licensing agreements, collaborations, and partnership activities to develop highly specific molecular diagnostic tests to monitor or select target therapeutics for addressing the pathogenesis of major diseases.

The report titled “Companion Diagnostics Market- Growth, Share, Opportunities and Competitive Analysis, 2016–2023” offers strategic insights into the overall companion diagnostics market along with the market size and estimates for the duration 2016 to 2023. The said research study covers in-depth analysis of multiple market segments based on type of indication, type of technologies and different geographical region. The indication type segment studied for analyzing the overall companion diagnostics market are oncology, cardiovascular diseases, virology and autoimmune diseases. On the basis of technology the companion diagnostics market has been segmented into polymerase chain reaction, immunohistochemistry, In-situ hybridization test, gene sequencing and others. In order to help strategic decision makers, the report also includes competitive profiling of the leading players in companion diagnostics market, attractive investment proposition and Porter’s five forces model, and market positioning of key manufacturers sections. Other in-depth analysis provided in the report includes:

Geographically, the Companion Diagnostics Market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Rest of Asia-Pacific
  • Latin America
  • Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2013-2023. Market growth rates for the forecast period 2016-2023 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global companion diagnostics market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global companion diagnostics market. This report concludes with company profiles section that highlights major information about the key players engaged in companion diagnostics market. In-depth competitive environment analysis and historical years (2013 & 2014) market size data are also provided in the report.

Thus, the research study provides a holistic view of the treatment global companion diagnostics market, offering market size and estimates for the period from 2016 to 2023, keeping in mind the above-mentioned factors.

Companion Diagnostics Market

 

Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Companion Diagnostics Market Portaiture
2.2 Global Companion Diagnostics Market, by Indication, 2015 (USD Mn)
2.3 Global Companion Diagnostics Market, by Technology, 2015 (USD Mn)
2.4 Companion Diagnostics Market Share, by Geography, 2015 (Value %)

Chapter 3 Companion Diagnostics : Market Dynamics and Outlook
3.1 Introduction, Facts and Figures
3.2 Epidemiology of Thyroid Disorders
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.1 Increased Focus on Cost Cutting in Drug Discovery and Development
3.3.1.2 Increased Popularity of Personalized Medicines
3.3.1.3 Rapid Advancements in Science and Technology
3.3.1.4 Increase in Prevalence of Cancer and Other Disorders
3.3.2 Challenges
3.3.2.1 High Cost Involved in Companion Diagnostics Development
3.3.1.2 Stringent Regulations
3.3.1.3 Need for Multidisciplinary Approach to Develop Efficient Companion Diagnostics
3.3.3 Opportunities
3.3.3.1 Increase in Number of Product Launches and Approvals
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis By Key Players, 2015 (Value %)
3.6 Vendor Landscape

Chapter 4 Companion Diagnostics Market, by Indications
4.1 Preface
4.2 Oncology
4.2.1. Breast Cancer
4.2.2. Colorectal Cancer
4.2.1. Gastric Cancer
4.2.2. Lung Cancer
4.2.1. Melanoma
4.2.2. Others
4.3 Cardiovascular Diseases
4.4 Infectious Diseases
4.5 Autoimmune Diseases

Chapter 5 Companion Diagnostics Market, by Technology
5.1 Overview
5.2 Polymerase Chain Reaction
5.3 Immunohistochemistry (IHC)
5.4 In-Situ Hybridization Test (ISH)
5.5 Gene Sequencing
5.6 Others

Chapter 6 Companion Diagnostics Market, By Geography
6.1 Overview
6.2 North America
6.2.1. U.S.
6.2.2. Canada
6.3 Europe
6.3.1. U.K.
6.3.2. Germany
6.3.3. Rest of Europe
6.4 Asia Pacific
6.4.1. Japan
6.4.2. China
6.4.3. Rest of Asia Pacific
6.4 Latin America
6.5 Middle East and Africa

Chapter 7 Company Profiles
7.1 Abbott Laboratories Inc.
7.1.1 Business Description
7.1.2 Financial Health and Budget Allocation
7.1.3 Product Portfolio
7.1.4 News Coverage
7.2 Agilent Technologies, Inc.
7.2.1 Business Description
7.2.2 Financial Health and Budget Allocation
7.2.3 Product Portfolio
7.2.4 News Coverage
7.3 bioMerieux SA
7.3.1 Business Description
7.3.2 Financial Health and Budget Allocation
7.3.3 Product Portfolio
7.3.4 News Coverage
7.4 Qiagen N.V.
7.4.1 Business Description
7.4.2 Financial Health and Budget Allocation
7.4.3 Product Portfolio
7.4.4 News Coverage
7.5 Roche Holdings AG
7.5.1 Business Description
7.5.2 Financial Health and Budget Allocation
7.5.3 Product Portfolio
7.5.4 News Coverage
7.6 Thermo Fisher Scientific
7.6.1 Business Description
7.6.2 Financial Health and Budget Allocation
7.6.3 Product portfolio
7.6.4 News Coverage
7.7 Ventana Medical Systems
7.7.1 Business Description
7.7.2 Financial Health and Budget Allocation
7.7.3 Product Portfolio
7.7.4 News Coverage
7.8 Myriad Genetics
7.8.1 Business Description
7.8.2 Financial Health and Budget Allocation
7.8.3 Product Portfolio
7.8.4 News Coverage
7.9 Leica Microsystems
7.9.1 Business Description
7.9.2 Financial Health and Budget Allocation
7.9.3 Product Portfolio
7.9.4 News Coverage
7.10 Other Notable Players

 

Based on the indication the global companion diagnostics market is segmented as follows:

  • Oncology
    • Breast Cancer
    • Colorectal Cancer
    • Gastric Cancer
    • Lung Cancer
    • Melanoma
    • Others(Neurology, Prostate Cancer, and Ovarian Cancer)
  • Cardiovascular Diseases
  • Infectious Diseases
  • Autoimmune Diseases

Companion diagnostic tests are used to identify suitable patients for administering specific drugs and monitoring the prognosis of drug effects on the disease. This concept of combining a drug with a diagnostic test is known as predictive medicine or personalized medicine. A companion diagnostic test has the ability to predict the risks of the disease and monitor its therapeutic response. The tests enable physicians to make decisions on the type of drugs and dosage administration and thereby reduce the mortality rates associated with diseases such as cancer and neurodegenerative disorders. On the basis of indication the global companion diagnostics market has been segmented as oncology, cardiovascular diseases, virology and autoimmune diseases. The oncology segment has been further segmented on the basis of various cancers such as breast cancer, colorectal cancer, gastric cancer, lung cancer, melanoma and other cancer.  The oncology segment held the largest market in the global companion diagnostics by indication and is expected to be the highest grossing segment through the forecast period. The major factors driving the oncology segment include development of majority of companion diagnostics for detection of various cancer biomarkers. The key driver for this market is an increase in research and development of targeted drugs, which require a corresponding companion diagnostic. Moreover, the development of nanotechnology and nanomedicine and the advancements in drug delivery are driving the field of personalized medicine.

Companion Diagnostics Market
  
 

Based on the technology the global companion diagnostics market is segmented as follows:

  • Polymerase Chain Reaction
  • Immunohistochemistry (IHC)
  • In-Situ Hybridization Test (ISH)
  • Gene Sequencing
  • Others (Monoclonal Antibodies Test and Cellular Immune Testing)

Companion diagnostic tests are used to identify suitable patients for administering specific drugs and monitoring the prognosis of drug effects on the disease. This concept of combining a drug with a diagnostic test is known as predictive medicine or personalized medicine. A companion diagnostic test has the ability to predict the risks of the disease and monitor its therapeutic response. On the basis of technology the companion diagnostics market has been segmented into polymerase chain reaction, immunohistochemistry, In-situ hybridization test, gene sequencing and others. The others segment includes tests such as monoclonal antibodies test and cellular immune testing. The polymerase chain reaction technique is the largest segment in the global companion diagnostics market. Factors such as high usage of the technique, cheaper rates and efficient results have driven the polymerase chain reaction technique market. Gene sequencing is expected to exhibit the highest growth rate during the forecast period. The development of next generation sequencing and third generation sequencing has resulted in the efficient detection of biomarkers, thus gaining momentum in the companion diagnostic market in the future.

Companion Diagnostics Market
  
 

For the purpose of this study, the global companion diagnostics market is categorized as follows:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa

Companion Diagnostics Market

The geographical segmentation of the global companion diagnostics market comprises North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. In base year 2015, North America accounted for the largest market in the global companion diagnostics. In North America, the US represented the largest market for companion diagnostic tests. This is mainly attributed to the growing demand for targeted therapeutics and the increase in the prevalence of the pathogenesis of various cancer ailments. In short, the demand for personalized medicines and diagnostics is driving the adoption of companion diagnostics. However, stringent regulations are expected to limit the growth of the market and delay the launch of various products. Asia Pacific is expected to grow at a highest rate during the forecast period due increased adoption, technological advancements, and demand for personalized medicine. Vendors in the market are focusing on several strategies such as licensing agreements, collaborations, and partnership activities to develop highly specific molecular diagnostic tests to monitor or select target therapeutics for addressing the pathogenesis of major diseases. Moreover, the increase in the prevalence of cancer and associated disorders, the increase in healthcare expenditure, and the increase in the level of awareness among the population. Thus, the APAC region is expected to adopt companion diagnostics tests at a rapid rate during the forecast period.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients